(secondQuint)Clinical Trial for Post-marketing Evaluation of Sheng Bai Oral Liquid.

 The Clinical trail is a multicenter, prospective, randomized controlled study.

 The planned sample size is 240 subjects.

 These subjects will be randomized (1:1) to treatment group (Platinum-based two medicine (carboplatin / cisplatin) plus Sheng Bai oral liquid) or control group ( Platinum-based two medicine (carboplatin / cisplatin) plus blank control).

 The study population includes the patients with non-small-cell lung cancer .

.

 Clinical Trial for Post-marketing Evaluation of Sheng Bai Oral Liquid@highlight

The purpose of the study is to evaluate the efficacy and safety of Sheng Bai oral liquid in prevention and treatment of the decrease of neutrophilics after chemotherapy in patients with non-small-cell lung cancer.

